Re-usable Respimat® Soft MistTM Inhaler Study

Boehringer Ingelheim262 enrolled

Overview

The study is to assess patient satisfaction with the inhaler attributes of the re-usable Respimat SMI (Spiriva, Striverdi or Spiolto) in patients with COPD, including patients who are Respimat SMI-experienced and Respimat SMI-naïve. This study also aims to examine patient preference for the re-usable Respimat SMI compared to the disposable Respimat SMI in Respimat SMI-experienced patients switching from a disposable to a re-usable Respimat SMI product at study entry.

Study Type

OBSERVATIONAL

Enrollment

262

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

RespimatDRUG

Soft Mist Inhaler product

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients fulfilling all the following inclusion criteria will be eligible for participation in the study: * Provision of signed informed consent prior to study data collection * Patient with COPD aged 40 years or older * Patient prescribed (or already receiving the disposable Respimat SMI and switched to) one of the following re-usable Respimat SMI products per the standard clinical practice: Spiriva 2.5 microgram inhalation solution; (2) Striverdi 2.5 microgram inhalation solution; and (3) Spiolto 2.5 microgram / 2.5 microgram inhalation solution * Patient unlikely to change their Respimat therapy during the 4-6 week observation period (in the opinion of the investigator) Exclusion Criteria: Patients fulfilling any of the following exclusion criteria will not be eligible for participation in the study: * Patient using a disposable Respimat SMI product during the study period * Patient who have had a severe COPD exacerbation requiring hospitalisation in the immediate 3 months prior to study entry * Patient participating in a clinical trial or any other non-interventional study of a drug or device at the time of enrolment * Visual, cognitive, motor or health impairment that, as judged by the investigator, may cause concern regarding the patient's ability to complete the questionnaires * Patient not fluent and literate in one of the main languages of the country

Locations (20)

Brussels - UNIV UZ Brussel

Brussels, Belgium

Clinique Notre-Dame de Grâce

Gosselies, Belgium

Outcomes

Primary Outcomes

Mean Total Patient Satisfaction and Preference Questionnaire (PASAPQ) Score

Total PASAPQ score is a measure of patient's satisfaction regarding the handling of the re-usable Respimat® SMI. The total score was the sum of the 13 items related to Performance and Convenience PASAPG domains (7 items for Performance domain: Q 1-5, 10-11, and 6 items for convenience domain: Q6-9, 12-13). Each PASAPQ item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the total and domain score, the items within each domain were first summed and then transformed to a 0 (least) or 100 (most) point scale, with higher scores indicating greater satisfaction: Performance score = 100 \*\[(Q1+Q2 +Q3+ Q4+Q5+Q10+Q11)-7\] /(49-7) Convenience score = 100 \*\[(Q6+ Q7+Q8+Q9+Q12+Q13)-6\] / (42-6) Total score = 100 \*\[(Q1+Q2 +Q3+Q4+ Q5+Q6 + Q7+Q8+ Q9+Q10+Q11+Q12+Q13)-13\] / (91-13)

Time frame: At follow-up assessment, 4 to 6 weeks after baseline.

Secondary Outcomes

Total Performance PASAPQ Score for All Patients at Study End (Follow-up Assessment)

The performance domain score of PASAPQ contained 7 items (Q 1-5 and 10-11), each item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the domain score, the items were first summed and then transformed to a 0 (least) to 100 (most) point scale, with higher scores indicating greater satisfaction: Performance score = 100 \* \[(Q1+ Q2+Q3+Q4+Q5+Q10+Q11)-7\] / (49-7)

Time frame: At follow-up assessment, 4 to 6 weeks after baseline.

Total Convenience PASAPQ Score for All Patients at Study End (Follow-up Assessment)

The convenience domain score of PASAPQ contained 6 items (Question 6-9 and 12-13), each item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the domain score, the items were first summed and then transformed to a 0 (least) to 100 (most) point scale, with higher scores indicating greater satisfaction: Convenience score = 100 \* \[(Q6+Q7+Q8+Q9+Q12+Q13)-6\] / (42-6)

Time frame: At follow-up assessment, 4 to 6 weeks after baseline.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Roeselare - HOSP AZ Delta

Menen, Belgium

Hvidovre Hospital

Hvidovre, Denmark

Vejle Hospital

Vejle, Denmark

TYKS, Keuhkosairauksien klinikka, Turku

Turku, Finland

Universitätsklinikum Aachen, AöR

Aachen, Germany

MECS Research GmbH, Berlin

Berlin, Germany

KPPK GmbH, Studienzentrum

Koblenz, Germany

Pneumologiezentrum Leipzig

Leipzig, Germany

...and 10 more locations

Overall Satisfaction Question With Inhaler for All Patients at Study End (Follow-up Assessment)

The overall satisfaction score of the PASAPQ asked for the overall satisfaction with the device used in the study (Question 14), answered using a 7-point scale ranging from 1 (very dissatisfied) to 7 (very satisfied). Reported is the number of patients by category.

Time frame: At follow-up assessment, 4 to 6 weeks after baseline.

Question on Willingness to Continue With Inhaler for All Patients at Study End (Follow-up Assessment)

To assess the willingness to continue with inhaler, the following questions was asked: "How would you feel about continuing to use the inhaler?", using a value from 0-100, with zero indicating that the patient is not willing to continue using the inhaler and 100 indicating that the patient is definitely willing to continue using the inhaler.

Time frame: At follow-up assessment, 4 to 6 weeks after baseline.

Questions on Ease of Handling of the Re-usable Respimat SMI for All Patients at Study End (Follow-up Assessment)

10 Questions regarding the Ease of Handling were asked, using a 7 point scale ranging from 1 (very dissatisfied) to 7 (very satisfied). Reported is the number of patients by answer category.

Time frame: At follow-up assessment, 4 to 6 weeks after baseline.

Difference in the Mean Total PASAPQ Score Between Study Entry and Study End in Respimat SMI-experienced Patients Who Switched From a Disposable to a Re-usable Respimat SMI Product

Difference in the mean Total PASAPQ score between study entry (baseline visit) and at study end (follow-up assessment) in Respimat SMI-experienced patients who switched from a disposable to a re-usable Respimat SMI product at study entry. The total score was the sum of the 13 items related to Performance and Convenience PASAPG domains (7 items for Performance domain: Q 1-5, 10-11, and 6 items for convenience domain: Q6-9, 12-13). Each PASAPQ item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the total and domain score, the items within each domain were first summed and then transformed to a 0 (least) or 100 (most) point scale, with higher scores indicating greater satisfaction.

Time frame: At study entry (baseline) and at study end (4 to 6 weeks after baseline).

Number of Patients With Preference for Re-usable or Disposable Respimat SMI at Study End in Respimat SMI-experienced Patients Who Switched From a Disposable to a Re-usable Respimat SMI Product

Number of patients with preference for re-usable or disposable Respimat SMI at study end (follow-up assessment), in Respimat SMI-experienced patients who switched from a disposable to a re-usable Respimat SMI product at study entry. To assess the preference for inhaler, following question was asked: "Comparing the re-usable with disposable inhaler, which inhaler do you prefer to use?"

Time frame: At follow-up assessment, 4 to 6 weeks after baseline.